Member Info for DP64

sky,
Fully agreed. TM should have generate internally to generate the SP to a acceptable level for the big boys.

T2,
So what is your argument for consolidation here?

I also do not think consolidation is a good one if they keep on issuing shares like what VAL did. The consequence of that Satu and George were forced to leave VAL. Hope our friend TM will not follow the same path.

UTA,
Great post and very true about our current life style. We need to change our lifestyle for betterment of the society.

Your reflection. Very good reflection

CB,
It seems you are very good friend of Satu and George. By the way how they are doing in their new venture.

Tim will be forced to explore in to new venture near future like Satu and George of Val. Few share holders got together to give them a lesson of lifetime and showed who is the boss not take it as a granted gravy train just by issuing the shares and maintain their lifestyle.

Hi Sado,
Many thanks for your wonderful summary. Fully agree it is matter of time before a bidding war starts.

T2,
Thanks for sharing your strategy.

gixer,
Many thanks for sharing the info. I like the following statement
statistically significant(P<0.001)
I was involved with some statistical modelling few years back.
statistically significant is something wonderful they achieved. It is matter of time BY Health is going to make an offer to buy us.
Our good friend IF should put all these links in PXS website.

Salford,
Wish her a good recovery and all the best to both of you. Once she recover you could suggest some Pranayam. Some example are as follows:
https://www.youtube.com/watch?v=-EH4D_DAvqc

Which may provide a novel evidence for the cardioprotective benefits of tomato.
WOW what a wonderful evidence. I take fruitflow daily and my blood pressure and heart rate are so normal. Now I know what is keeping all these normal.

gixer,
Many thanks for sharing your great find.
Conclusion: Fruitflow effectively inhibited platelet granule secretion via down-regulating platelet Src/PLC-?2/PKC signaling pathway in vitro , which may provide a novel evidence for the cardioprotective benefits of tomato.
It is definitely something good and waiting to explode. I will put some additional fund now before it explode in near future.

Hi gixer,
Great find. Wonderful detective work. If you have a contact e-mail address of our good friend IF please send all these links so that he could include all these great research in PXS website.

Num4,
Wonderfully researched post. Please keep here posted if you get those information.
Haribol

T2,
Great post. Fully agree they should go ahead with poral solution and then add capsule. It is simple logic if you try to put everything together at the beginning then the project become too complicated and did not see the light at all. Just start what you have and then add subsequently. Time is really running high for TM to show something to avoid a similar situation like Satu and George of VAL.

T2,
Great post our resident hero. Please keep it up.
Haribol

Well-done Mr. Parker to align your interest along with us shareholder. Hope your colleagues will also follow you as an example especially TM.

https://www.edisongroup.com/publication/sdc-1801s-clinical-plan-modified/30232
Sareum’s lead asset SDC-1801 is inching closer to completing its preclinical toxicology studies, although the decision to pursue a capsule alternative to the original suspension formulation, at the cost of a further delay in the clinical trial application (CTA) filing (now expected mid-2022), comes as a surprise. Management asserts that the new formulation adds value to the programme (removing the need to develop capsules at a later stage) and is supported by £4.6m of funds raised in calendar Q221/Q321. While we see merits in the strategy, continued delays may concern the market. Encouragingly, out-licensed asset, SRA737, seems to be gaining traction after Sierra Oncology’s decision to reassess it in combination with other targeted therapies. We expect that the next few months will be crucial for Sareum.
SDC-1801 to be developed in capsule formulation

SDC-1801, Sareum’s lead TYK2/JAK1 inhibitor, is on-track to complete the final preclinical toxicology studies by the end of 2021 and the company has appointed external consultants to help develop the clinical plan and choose the optimal first indication for the clinical studies. A key development in SDC-1801’s clinical plans has been Sareum’s decision to develop its drug in a capsule form versus the original dry powder suspension. We believe these efforts towards optimising the formulation/administration could be a sensible step, although the repetitive delays in taking the asset to the clinic may concern investors.

Encouraging signals for SRA737

The recent in-licensing by Sierra of BET inhibitor AZD5153 from AstraZeneca and subsequent disclosure by Sierra that it may test the compound in combination with SRA737 in two Phase I trials (haematological malignancies and solid tumours) is a positive sign for Sareum, which owns a 27.5% economic interest in SRA737. Sierra will also be undertaking a third Phase I study assessing SRA737 along with immunotherapy/low-dose gemcitabine. First patient dosing in any one study will trigger a $2m milestone payment (thus $0.55m to Sareum).

Financing in place after equity raise

Equity raisings in calendar Q221/Q321 (totalling £4.6m) should allow Sareum to advance SDC-1801 to the clinic and complete preclinical studies on SDC-1802, as per the management. However, additional funds would be required (possibly through out-licensing deals or equity raises) to progress the programmes further.

Those who are in favour of TM to give another chance please show that he kept a single promise in last 12/13 years. If you are in a job and could not keep a single promise to your boss in 12/13 years careers do you think your boss will keep on hiring you. SAR is a public limited company and not his personal milking cow company. He needs to show he is capable of running a company and making a deal not just keeping empty promise telling us the bu****t that tyk2 is a billion pound compound. So time has come for him like Satu and George of VAL.